• Ginkgo Bioworks (NYSE:DNA) has soared ~14% higher in post-market trading Tuesday after posting Q3 results that beat on both lines and raising its 2024 revenue outlook range.
• The cell programming platform company now sees full-year revenue of $215M-235M, up from $170M-$190M prior. Consensus is $185.52M.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。